It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Optimizing your budget with zero-based techniques can significantly improve cash flow. Explore methods that work for you.
23,484 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
New data shows high-end metro areas are turning over listings faster than mid-priced markets, upending expectations a...
As the 10-year Treasury crosses 4.6%, ETF dynamics for VOO and IVV face renewed scrutiny. Markets weigh rate paths, i...
MicroStrategy, the world's largest corporate holder of Bitcoin, announced a major bond buyback this week, signaling a...
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
America’s debt has surged to WWII-era levels even as growth accelerates. Here’s what the numbers show and why investo...
Tokenized equities on-chain may alter how investors diversify. As banks test cross-rail settlement, the case for broa...
Circle announces a $222 million Arc token presale at a $3 billion FDV, drawing major investors as quarterly revenue g...
The trillion-dollar club has swelled to 14 as of late May 2026, led by AI-enabled tech giants. The combined market ca...
The GENIUS Act creates a federal framework for dollar-backed stablecoins, setting rules on issuance, reserve backing,...
Robinhood launched a new layer-2 blockchain to tokenized real-world assets, yet the initial trading frenzy centered o...
A large fund trimmed its DigitalBridge position, sparking questions about stake moves, stock momentum, and how invest...